Inactive Instrument

Dimension Therapeutics Inc Share Price

Equities

Duration

Period

Style

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”	02/10/17	GL
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”	19/09/17	GL
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx	18/09/17	GL
Dimension Therapeutics : OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors	05/09/17	PR
Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information	31/08/17	BU

Managers	Title	Age	Since
Thomas Kassberg PSD	President	63	06/11/17
Stephanie Haller CTO	Chief Tech/Sci/R&D Officer	-	31/10/14
Karah Parschauer BRD	Director/Board Member	46	06/11/17

Members of the board	Title	Age	Since
Karah Parschauer BRD	Director/Board Member	46	06/11/17

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B